[1] CHANG C C， HUH H Y， CADIGAN K M， et al. Molecular cloning and functional expression of human acyl-coenzyme A：cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells[J]. J Biol Chem， 1993， 268(28)： 20747-20755.
[2] KINNUNEN P M， DEMICHELE A， LANGE L G. Chemical modification of acyl-CoA：cholesterol O-acyltransferase. 1. Identification of acyl-CoA：cholesterol O-acyltransferase subtypes by differential diethyl pyrocarbonate sensitivity[J]. Biochemistry， 1988， 27(19)： 7344-7350.
[3] MEINER V， TAM C， GUNN M D， et al. Tissue expression studies on the mouse acyl-CoA： cholesterol acyltransferase gene (Acact)： findings supporting the existence of multiple cholesterol esterification enzymes in mice[J]. J Lipid Res， 1997， 38(9)： 1928-1933.
[4] CASES S， NOVAK S， ZHENG Y W， et al. ACAT-2， a second mammalian acyl-CoA：cholesterol acyltransferase. Its cloning， expression， and characterization[J]. J Biol Chem， 1998， 273(41)： 26755-26764.
[5] LEON C， HILL J S， WASAN K M. Potential role of acyl-coenzyme A：cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs[J]. Pharm Res， 2005， 22(10)： 1578-1588.
[6] RUDEL L L， LEE R G， COCKMAN T L. Acyl coenzyme A： cholesterol acyltransferase types 1 and 2： structure and function in atherosclerosis[J]. Curr Opin Lipidol， 2001， 12(2)： 121-127.
[7] CHENG D， CHANG C C， QU X， et al. Activation of acyl-coenzyme A：cholesterol acyltransferase by cholesterol or by oxysterol in a cell-free system[J]. J Biol Chem， 1995， 270(2)： 685-695.
[8] GUO Z Y， LIN S， HEINEN J A， et al. The active site His-460 of human acyl-coenzyme A：cholesterol acyltransferase 1 resides in a hitherto undisclosed transmembrane domain[J]. J Biol Chem， 2005， 280(45)： 37814-37826.
[9] JOYCE C W， SHELNESS G S， DAVIS M A， et al. ACAT1 and ACAT2 membrane topology segregates a serine residue essential for activity to opposite sides of the endoplasmic reticulum membrane[J]. Mol Biol Cell， 2000， 11(11)： 3675-3687.
[10] LIN S， LU X， CHANG C C， et al. Human acyl-coenzyme A：cholesterol acyltransferase expressed in chinese hamster ovary cells： membrane topology and active site location[J]. Mol Biol Cell， 2003， 14(6)： 2447-2460.
[11] SAKASHITA N， MIYAZAKI A， TAKEYA M， et al. Localization of human acyl-coenzyme A： cholesterol acyltransferase-1 (ACAT-1) in macrophages and in various tissues[J]. Am J Pathol， 2000， 156(1)： 227-236.
[12] REPA J J， BUHMAN K K， FARESE R V Jr， et al. ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse： impact on hepatic cholesterol homeostasis[J]. Hepatology， 2004， 40(5)： 1088-1097.
[13] SAKASHITA N， MIYAZAKI A， CHANG C C， et al. Acyl-coenzyme A：cholesterol acyltransferase 2 (ACAT2) is induced in monocyte-derived macrophages： in vivo and in vitro studies[J]. Lab Invest， 2003， 83(11)： 1569-1581.
[14] CHANG C， DONG R， MIYAZAKI A， et al. Human acyl-CoA：cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis[J]. Acta Biochim Biophys Sin (生物化学与生物物理学报)， 2006， 38(3)： 151-156.
[15] WANG Q， LIU Z G， TIAN J， et al. The study on cholesterol induced unfolded protein response and acyl-CoA cholesterol acyltransferase-2 expression[J]. Chin J Arterioscler（中国动脉硬化杂志）， 2007， 15(4)： 253-255.
[16] MAZIERE C， BARBU V， AUCLAIR M， et al. Interleukin 1 stimulates cholesterol esterification and cholesterol deposition in J774 monocytes-macrophages[J]. Biochim Biophys Acta， 1996， 1300(1)： 30-34.
[17] YANG J B， DUAN Z J， YAO W， et al. Synergistic transcriptional activation of human acyl-coenzyme A： cholesterol acyltransterase-1 gene by interferon-gamma and all-trans-retinoic acid THP-1 cells[J]. J Biol Chem， 2001， 276(24)： 20989-20998.
[18] HORI M， MIYAZAKI A， TAMAGAWA H， et al. Up-regulation of acyl-coenzyme A：cholesterol acyltransferase-1 by transforming growth factor-beta1 during differentiation of human monocytes into macrophages[J]. Biochem Biophys Res Commun， 2004， 320(2)： 501-505.
[19] FURUKAWA K， HORI M， OUCHI N， et al. Adiponectin down-regulates acyl-coenzyme A：cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages[J]. Biochem Biophys Res Commun， 2004， 317(3)： 831-836.
[20] PRAMFALK C， DAVIS M A， ERIKSSON M， et al. Control of ACAT2 liver expression by HNF1[J]. J Lipid Res， 2005， 46(9)： 1868-1876.
[21] YANG L， YANG J B， CHEN J， et al. Enhancement of human ACAT1 gene expression to promote the macrophage-derived foam cell formation by dexamethasone[J]. Cell Res， 2004， 14(4)： 315-323.
[22] BAI Z， CHENG B， YU Q， et al. Effects of leptin on expression of acyl-coenzymea： cholesterol acyltransferases-1 in cultured human monocyte-macrophages[J]. J Huazhong Univ Sci Technolog Med Sci（华中科技大学学报：医学版）， 2004， 24(6)： 563-565， 590.
[23] YAGYU H， KITAMINE T， OSUGA J， et al. Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia[J]. J Biol Chem， 2000， 275(28)： 21324-21330.
[24] RUDEL L L， LEE R G， PARINI P. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia[J]. Arterioscler Thromb Vasc Biol， 2005， 25(6)： 1112-1118.
[25] FAZIO S， MAJOR A S， SWIFT L L， et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages[J]. J Clin Invest， 2001， 107(2)： 163-171.
[26] RONG J X， KUSUNOKI J， OELKERS P， et al. Acyl-coenzymeA (CoA)：cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation[J]. Arterioscler Thromb Vasc Biol， 2005， 25(1)： 122-127.
[27] IKENOYA M， YOSHINAKA Y， KOBAYASHI H， et al. A selective ACAT-1 inhibitor， K-604， suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels[J]. Atherosclerosis， 2007， 191(2)： 290-297.
[28] HUTTER-PAIER B， HUTTUNEN H J， PUGLIELLI L， et al. The ACAT inhibitor CP-113，818 markedly reduces amyloid pathology in a mouse model of Alzheimer′s disease[J]. Neuron， 2004， 44(2)： 227-238.
[29] HUTTUNEN H J， KOVACS D M. ACAT as a drug target for Alzheimer′s disease[J]. Neurodegener Dis， 2008， 5(3-4)： 212-214.
[30] HUTTUNEN H J， PEACH C， BHATTACHARYYA R， et al. Inhibition of acyl-coenzyme A： cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway[J]. FASEB J， 2009， 23(11)： 3819-3828.
[31] DING D R， SHEN J K. Current status of studies on Acy1-CoA：Cholesterol Acyltransferase(ACAT)inhibitors[J]. Chine New Drugs J（中国新药杂志）， 2005， 14(4)： 396-399.
[32] GIOVANNONI M P， PIAZ V D， VERGELLI C， et al. Selective ACAT inhibitors as promising antihyperlipidemic， antiathero-sclerotic and anti-Alzheimer drugs[J]. Mini Rev Med Chem， 2003， 3(6)： 576-584.
[33] JUNQUERO D， OMS P， CARILLA-DURAND E， et al. Pharmacological profile of F 12511， (S)-2′，3′， 5′-trimethyl-4′-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A： cholesterol acyltransferase inhibitor[J]. Biochem Pharmacol， 2001， 61(1)： 97-108.
[34] ASANO S， BAN H， KINO K， et al. Synthesis and structure-activity relationships of N-(4-amino-2，6-diisopropylphenyl)-N′-(1，4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents[J]. Bioorg Med Chem， 2009， 17(13)： 4636-4646.
[35] MATSUDA D， OHSHIRO T， OHBA M， et al. The molecular target of rubimaillin in the inhibition of lipid droplet accumulation in macrophages[J]. Biol Pharm Bull， 2009， 32(8)： 1317-1320.
[36] MIIKE T， SHIRAHASE H， JINO H， et al. Effects of an anti-oxidative ACAT inhibitor on apoptosis/necrosis and cholesterol accumulation under oxidative stress in THP-1 cell-derived foam cells[J]. Life Sci， 2008， 82(1-2)： 79-84.